Tumour-infiltrating CD4(+) and CD8(+) lymphocytes as predictors of clinical outcome in glioma
about
Prospects of immune checkpoint modulators in the treatment of glioblastomaExogenous IGFBP-2 promotes proliferation, invasion, and chemoresistance to temozolomide in glioma cells via the integrin β1-ERK pathwayLPS alters the immuno-phenotype of glioma and glioma stem-like cells and induces in vivo antitumor immunity via TLR4The prognostic role of preoperative serum albumin levels in glioblastoma patients.Pre-treatment neutrophil-to-lymphocyte ratio is associated with neutrophil and T-cell infiltration and predicts clinical outcome in patients with glioblastomaIdentification of a five B cell-associated gene prognostic and predictive signature for advanced glioma patients harboring immunosuppressive subtype preference.The Dynamics of Interactions Among Immune and Glioblastoma Cells.MiR-15a/16 deficiency enhances anti-tumor immunity of glioma-infiltrating CD8+ T cells through targeting mTOR.Serglycin as a potential biomarker for glioma: association of serglycin expression, extent of mast cell recruitment and glioblastoma progression.Immune classifications with cytotoxic CD8+ and Th17 infiltrates are predictors of clinical prognosis in glioblastoma.Immune Checkpoint Inhibitors in Gliomas.Ingramon, a Peptide Inhibitor of MCP-1 Chemokine, Reduces Migration of Blood Monocytes Stimulated by Glioma-Conditioned Medium.Adoptive Cellular Therapy (ACT) for Cancer Treatment.Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma.Co-inhibitory blockade while preserving tolerance: checkpoint inhibitors for glioblastoma.Engineering challenges for brain tumor immunotherapy.Tumor-infiltrating memory T-lymphocytes for prognostic prediction in cancer patients: a meta-analysisCCL2 Produced by the Glioma Microenvironment Is Essential for the Recruitment of Regulatory T Cells and Myeloid-Derived Suppressor Cells.Tumor-infiltrating CD8(+) T lymphocytes associated with clinical outcome in anal squamous cell carcinoma.PD-1 blockade restores impaired function of ex vivo expanded CD8+ T cells and enhances apoptosis in mismatch repair deficient EpCAM+PD-L1+ cancer cells.Preoperative inflammation markers and IDH mutation status predict glioblastoma patient survival.Functional differences between PD-1+ and PD-1- CD4+ effector T cells in healthy donors and patients with glioblastoma multiforme.Peripheral Blood Regulatory T-Cell and Type 1 Helper T-Cell Population Decrease after Hepatic Artery Embolization.Tregs in gliomas - the jury is still out.Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract CaDendritic cell vaccines based on immunogenic cell death elicit danger signals and T cell-driven rejection of high-grade glioma.Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase 1 cohorts of CheckMate 143.CD4+ and Perivascular Foxp3+ T Cells in Glioma Correlate with Angiogenesis and Tumor Progression.Genetic and immune features of resectable malignant brainstem gliomas.Low preoperative prognostic nutritional index predicts poor survival in patients with newly diagnosed high-grade gliomas.Targeting Neoantigens in Glioblastoma: An Overview of Cancer Immunogenomics and Translational Implications.Poly(I:C) primes primary human glioblastoma cells for an immune response invigorated by PD-L1 blockade.Neutrophils, a candidate biomarker and target for radiation therapy?Regulated intratumoral expression of IL-12 using a RheoSwitch Therapeutic System® (RTS®) gene switch as gene therapy for the treatment of glioma.Neutrophilia as a biomarker for overall survival in newly diagnosed high-grade glioma patients undergoing chemoradiation.Antitumor and Immunomodulatory Activities of Ganoderma lucidum Polysaccharides in Glioma-Bearing Rats.Prognostic significance of PD-L1 expression and tumor infiltrating lymphocytes in large cell neuroendocrine carcinoma of lungChromogenic Multiplex Immunohistochemistry Reveals Modulation of the Immune Microenvironment Associated with Survival in Elderly Patients with Lung Adenocarcinoma
P2860
Q28081371-FB38427F-6851-4829-B28D-3625896A8247Q30402547-434CBB93-7CFF-494B-8665-80EC20752624Q33824394-7A9CABE5-32C4-429C-90CD-FC16CE734FF5Q35164608-46C6FE6A-8182-4505-8F23-84E8C4AF4E03Q35765180-17737920-6865-47C7-9C32-12B1AC149855Q37687506-F9EA8F6C-A314-4446-9FD3-841641176065Q38557236-93943FE8-A502-4108-BCB3-78EFDC88D24AQ38652482-35640F6B-C829-480E-837E-3EE557303ED4Q38690536-791960F5-BE3C-4BBF-809C-75A28DAAECF3Q38691992-D6502532-A0B9-412A-8E66-757939AFF7FEQ38743793-5D9A807F-84E5-4319-B88A-BDBD55398599Q38791716-7A6F7BD2-B4AD-44E2-8272-E09DABDC98C2Q38848219-F1D5D593-18E2-40E6-A3F9-800C79EE2258Q38890122-2AF682F9-4B2F-48C2-A096-C905CCB46F21Q39160992-D148A4AE-64E3-413B-9065-68C05224882AQ39381281-E71DC044-3F30-408E-9DA3-C0D16E2EDCC5Q39777761-775D38EF-5271-42AF-92FB-15761190BBDBQ40619963-4BB2F15A-945E-49B1-93B3-0918C3B33337Q41044428-7802EE91-EE6C-450E-9614-F3FAA99DFD41Q41057575-19A695DF-D3FA-4F2B-88B6-A6D8DFA150C1Q41472948-913A5361-E802-46DB-8259-63841DB2D121Q41576716-76426E09-56FA-48F8-8266-C487ADF27018Q41652033-992D331A-C7E1-43DE-BF0B-F68E4CC23FCDQ42396516-FA9EE3B4-E32B-4979-AFA7-3FA3717C4AC9Q46540302-F8455FAC-3EDB-432E-97CB-B4D18D122F4FQ46586294-DCE68A9E-6BA5-43EE-85A5-F72364DF2DFAQ46675575-43A2BF75-013B-4F4F-8721-826453AFB126Q47126472-877545E7-7E61-4D9C-9FFE-4991CA9B7D2FQ47152219-653BF714-5416-4295-BF41-C491C7CF4376Q48361595-AA275824-456C-4C27-AB7F-E2ABB011EC2EQ50130464-D9B1581D-1CCE-495A-9E2F-4F17E8DA1893Q50423292-B7215083-205B-4E9B-B6EE-0F9ADB792A9CQ51802063-30D3F4A5-BEE4-4094-A0B3-257851191A4BQ54213332-C52A7FE8-D68E-4776-BBD4-1B425DE4D043Q55315483-711AE7ED-F7FF-4B83-B690-95DB39A259B4Q55457369-0D38D6B1-DE73-429C-AA26-747E2B8AE86AQ58733942-26560DAA-9BF2-4260-989E-C74DC35DD9C7Q58742661-A8AF1BF7-FFD3-4802-9F3D-9892F544B05C
P2860
Tumour-infiltrating CD4(+) and CD8(+) lymphocytes as predictors of clinical outcome in glioma
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Tumour-infiltrating CD4(+) and ...... of clinical outcome in glioma
@ast
Tumour-infiltrating CD4(+) and ...... of clinical outcome in glioma
@en
type
label
Tumour-infiltrating CD4(+) and ...... of clinical outcome in glioma
@ast
Tumour-infiltrating CD4(+) and ...... of clinical outcome in glioma
@en
prefLabel
Tumour-infiltrating CD4(+) and ...... of clinical outcome in glioma
@ast
Tumour-infiltrating CD4(+) and ...... of clinical outcome in glioma
@en
P2093
P2860
P356
P1476
Tumour-infiltrating CD4(+) and ...... of clinical outcome in glioma
@en
P2093
P2860
P2888
P304
P356
10.1038/BJC.2014.162
P407
P577
2014-04-01T00:00:00Z
P6179
1035077389